FibroGen (NASDAQ:FGEN) Shares Cross Below 200 Day Moving Average – What’s Next?

FibroGen, Inc. (NASDAQ:FGEN) shares crossed below its 200-day moving average during trading on Tuesday . The stock has a 200-day moving average of $0.46 and traded as low as $0.45. FibroGen shares last traded at $0.46, with a volume of 608,198 shares.

Analyst Upgrades and Downgrades

Several brokerages have recently commented on FGEN. William Blair reaffirmed a “market perform” rating on shares of FibroGen in a research report on Wednesday, November 13th. StockNews.com assumed coverage on FibroGen in a report on Wednesday. They issued a “hold” rating for the company. Finally, HC Wainwright raised FibroGen to a “strong-buy” rating in a research report on Tuesday, December 17th.

FibroGen Trading Down 2.6 %

The firm has a market cap of $46.68 million, a P/E ratio of -0.38 and a beta of 0.75. The business’s 50-day moving average is $0.48 and its two-hundred day moving average is $0.46.

FibroGen (NASDAQ:FGEN) last posted its earnings results on Tuesday, November 12th. The biopharmaceutical company reported ($0.17) EPS for the quarter, beating the consensus estimate of ($0.38) by $0.21. The company had revenue of $46.33 million for the quarter, compared to the consensus estimate of $34.00 million. During the same period last year, the company posted ($0.52) earnings per share. On average, analysts anticipate that FibroGen, Inc. will post -0.8 earnings per share for the current year.

Hedge Funds Weigh In On FibroGen

Several hedge funds and other institutional investors have recently modified their holdings of FGEN. Franklin Street Advisors Inc. NC increased its holdings in shares of FibroGen by 100.0% in the 4th quarter. Franklin Street Advisors Inc. NC now owns 200,000 shares of the biopharmaceutical company’s stock worth $106,000 after acquiring an additional 100,000 shares during the period. Sei Investments Co. increased its stake in shares of FibroGen by 38.4% in the second quarter. Sei Investments Co. now owns 149,342 shares of the biopharmaceutical company’s stock valued at $133,000 after purchasing an additional 41,442 shares during the period. Squarepoint Ops LLC bought a new stake in shares of FibroGen during the second quarter valued at approximately $145,000. FMR LLC boosted its position in shares of FibroGen by 21.8% during the third quarter. FMR LLC now owns 383,258 shares of the biopharmaceutical company’s stock worth $153,000 after buying an additional 68,569 shares during the period. Finally, Cubist Systematic Strategies LLC grew its holdings in FibroGen by 3,906.9% in the 2nd quarter. Cubist Systematic Strategies LLC now owns 287,332 shares of the biopharmaceutical company’s stock worth $256,000 after buying an additional 280,161 shares in the last quarter. Institutional investors and hedge funds own 72.71% of the company’s stock.

About FibroGen

FibroGen, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Pamrevlumab, a human monoclonal antibody targeting connective tissue growth factor that is in Phase III clinical development for the treatment of locally advanced pancreatic cancer; and Roxadustat, an oral small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes.